CORCEPT THERAPEUTICS INC

CORTNASDAQ

🏆 #658 by market capEarnings Nov 3US Equity

$460.37▼ $11.37 (−2.47%)

Simulated price

1h—

24h▼ 2.5%

7d—

14d—

30d—

1y—

🏦Market Cap

$12.35B

Mid Cap

📈Revenue Growth (YoY)

+16.0%

Healthy

📊Gross Margin

98.3%

High

💵FCF Margin

14.9%

Healthy

⚖️P/S Ratio

14.8x

Expensive

Otter Score

Weak

No chart data available for CORT.

Trading Snapshot

Day Range: $456.58 – $465.63
52-Week Range: $28.66 – $122.21
Volume: $3.47B
Avg Volume: $4.28B
Shares Outstanding: 108.1M
Next Earnings: Oct 7, 2026

Fundamentals Snapshot

Annual Revenue: $761M
Last Q Revenue: $256M
P/E Ratio: 223.5
P/S Ratio: 14.8x
EPS (TTM): $0.43
Dividend Yield: —

Why Investors Own CORT

✓High-growth profile — revenue up +14.5% YoY with expanding US Equity exposure.
✓Healthy economics — 26% gross margin and 25% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$761M▲ +12.8% YoY

Gross Margin (TTM)

25.9%▲ +2.0% YoY

Operating Income (TTM)

$137M▲ +12.8% YoY

Free Cash Flow (TTM)

$193M▲ +12.8% YoY

About CORCEPT THERAPEUTICS INC

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

🦦